Complete Scientific Guide to Spirulina

Executive summary and quick facts

Spirulina is a dried, protein-rich biomass of the filamentous cyanobacteria Arthrospira platensis and A. maxima. It is a nutritious whole food with a credible but modest evidence base for cardiometabolic, antioxidant and immune-related outcomes, and its safety depends heavily on the purity of the batch.

What the evidence supports, in brief:

• Human trials of 1–8 g/day for 4–24 weeks most consistently report small improvements in blood lipids, some improvement in blood pressure and fasting glucose, and reduced markers of exercise-induced oxidative stress.
• Evidence for allergic rhinitis, anemia in older adults and immune modulation is promising but rests on small, short, heterogeneous trials.
• Spirulina is generally well tolerated at ≤10 g/day. Most adverse events are mild gastrointestinal effects. Rare case reports describe autoimmune flares and rhabdomyolysis.
• The main safety risk is contamination (microcystins from co-occurring cyanobacteria, heavy metals), not the organism itself.
• Spirulina should be avoided in phenylketonuria and used cautiously in autoimmune disease and in people taking immunosuppressants or anticoagulants.
• Its vitamin B12 is mostly pseudovitamin B12, which is not a reliable B12 source for humans.

Quick fact	Detail
Organism	Arthrospira platensis / A. maxima (cyanobacteria; "blue-green algae")
Protein	About 55–70% of dry weight, all essential amino acids present
Signature pigment	C-phycocyanin, typically 10–20% of dry weight
Signature lipid	γ-linolenic acid (GLA), about 0.5–1.5% of dry weight
Typical supplement dose	1–5 g/day (trials: 1–10 g/day)
Common forms	Powder, tablets, capsules, extracts (phycocyanin), flakes
Key risks	Contamination, phenylalanine content, immune-activating case reports
Regulatory status	Dietary supplement / food in most markets; phycocyanin approved as a colorant in the US

Evidence grades in this guide are the author's qualitative judgments, loosely modelled on GRADE, and are not formal GRADE assessments.

Ingredient definition and identity

"Spirulina" is a commercial name for the dried biomass of filamentous, spiral-shaped cyanobacteria, now taxonomically placed in the genus Arthrospira. The two species used almost exclusively in commerce are A. platensis and A. maxima. Despite the common label "blue-green algae", spirulina is a prokaryote: it has no nucleus and no chloroplasts, and it performs oxygenic photosynthesis with its own thylakoid membranes.

The naming is a persistent source of confusion. The genus Spirulina (Turpin, 1827) is a distinct group of cyanobacteria. The edible species were historically assigned to it, and the supplement trade kept the name. Under current taxonomy, the product sold as spirulina is Arthrospira. Labels, regulations and most clinical papers still use "Spirulina", and this guide follows that convention.

Identity matters for three practical reasons. First, other cyanobacteria (for example Aphanizomenon flos-aquae, "AFA") are marketed as "blue-green algae" but have a different composition and contamination profile. Second, spirulina is not interchangeable with eukaryotic microalgae such as Chlorella, whose rigid cellulose-containing wall changes digestibility. Third, strain and growth conditions alter protein, pigment and fatty-acid content, so "spirulina" describes a range of products, not one defined substance.

Attribute	Spirulina
Common names	Spirulina, blue-green algae, dihé (Kanembu), tecuitlatl (Nahuatl)
Commercial species	Arthrospira platensis, A. maxima
Cell type	Prokaryotic; multicellular filament (trichome) in a left-handed helix
Cell wall	Gram-negative-type; peptidoglycan and polysaccharide layers, no cellulose
Typical colour	Blue-green (phycocyanin + chlorophyll a + carotenoids)

Botanical and chemical classification

Taxonomic placement. Spirulina belongs to the domain Bacteria, phylum Cyanobacteria, order Oscillatoriales, family Microcoleaceae (older literature uses Phormidiaceae), genus Arthrospira. Cyanobacterial taxonomy is still being revised with molecular data, so order and family assignments differ between databases. Species delimitation inside Arthrospira is also unsettled: strains labelled A. platensis are genetically diverse, and some authors treat several named species as variants.

Chemical classification. Chemically, spirulina is a whole-cell biomass, not a single compound. For regulatory and analytical purposes it is described by its macro- and micro-constituent classes:

• Proteins and chromoproteins, dominated by the phycobiliproteins C-phycocyanin (blue) and allophycocyanin.
• Lipids, mostly glycolipids and phospholipids, with a polyunsaturated fraction rich in γ-linolenic acid (18:3 n-6) and palmitic acid.
• Polysaccharides, including glycogen-like storage glucans and sulfated polysaccharides such as calcium spirulan.
• Tetrapyrroles and isoprenoids: chlorophyll a, carotenoids (β-carotene, zeaxanthin, myxoxanthophyll, echinenone) and phycobilins.
• Minerals and vitamins, notably iron, magnesium, potassium, and several B vitamins and provitamin A.

Functional classification. In nutrition science spirulina is a microbial-biomass protein (single-cell protein). In regulatory language it is a food, a dietary supplement ingredient or, for its pigment extract, a colour, depending on jurisdiction and use.

Origin, cultivation and source

Natural habitat. Spirulina grows naturally in warm, shallow, highly alkaline lakes in subtropical regions, with pH commonly 9–11 and high carbonate and bicarbonate content. Classic sites include Lake Chad and neighbouring Sahelian lakes and Lake Texcoco in the Valley of Mexico. Few competing organisms tolerate these conditions, which is why spirulina can dominate and why alkaline culture has become the basis of commercial production.

Commercial cultivation. Nearly all commercial spirulina is farmed. Production methods fall into three groups:

• Open raceway ponds: shallow (15–30 cm) paddlewheel-mixed channels, by far the most common system, used from small farms to industrial operations.
• Closed photobioreactors: tubular or flat-panel systems with better contamination control and higher cell density, at higher cost and with scaling and overheating challenges.
• Indoor or hybrid systems: LED-lit tanks, mainly for research, high-value phycocyanin or controlled-quality niches.

The usual growth medium is a mineral-salt formulation derived from Zarrouk's medium (1966): sodium bicarbonate, nitrate, phosphate, potassium, magnesium, iron and trace elements in water. Optimal growth occurs at roughly 30–37 °C and pH 9–10.5 with strong light. The high pH is a natural biosecurity barrier against many bacteria and most eukaryotic algae, but not against all cyanobacteria.

Harvest and drying. Filaments are long enough to be harvested by filtration through fine mesh. The paste is washed, pressed and then dried, most often by spray-drying, low-temperature belt drying or sun drying. Drying method affects colour, pigment retention and microbial load.

Where it is produced. China is generally reported as the largest producer, followed by other Asian countries, the United States (notably Hawaii and California), and smaller production in Africa, Europe and Latin America. Reported global production is in the tens of thousands of tonnes per year; exact figures vary by source and are not verified here.

Source quality. Water source, nutrient inputs, pond hygiene, harvest speed and drying all feed into final composition and safety, which is why "origin" is a meaningful quality variable and not just a marketing term.

History and traditional use

Aztec use. Spanish chroniclers of the 16th century described a blue-green cake sold in the markets of Tenochtitlan. Called tecuitlatl in Nahuatl, it was harvested from Lake Texcoco, dried and eaten, often with maize preparations. Lake drainage and ecological change ended this practice in central Mexico.

Kanembu use. Around Lake Chad, the Kanembu people have for generations collected spirulina from natural pools, sun-dried it into cakes called dihé and used it in sauces and soups. This tradition persists locally and is the best-documented continuous use of spirulina as a food.

Scientific rediscovery. In the 1960s the French phycologist Jean Léonard documented the Lake Chad harvest, and Mexican industrial work (including the Sosa Texcoco soda plant) reported spirulina in alkaline waters. This prompted research on cultivation and nutrition. In 1974, the UN World Food Conference described spirulina as a promising food for the future, which supported early development programmes against malnutrition.

Space and sustainability. Spirulina has been studied in closed-loop life-support research (including NASA and ESA programmes) because it is fast-growing, protein-rich and oxygen-producing. Recent interest centres on its low land and freshwater footprint relative to conventional protein crops.

Traditional medical use. Unlike many botanicals, spirulina has no deep, codified use in traditional medical systems such as Ayurveda or Traditional Chinese Medicine. Traditional use is overwhelmingly as a food. Most health claims arise from 20th-century nutrition science and the modern supplement industry, which is an important limit on any "ancient remedy" framing.

Modern nutraceutical use

Today spirulina is used in four overlapping markets:

• Dietary supplements. Tablets, capsules and powders, marketed for general nutrition, energy, antioxidant support, cardiometabolic health, immune support and sports recovery. This is the largest consumer use.
• Food and beverages. Powder added to smoothies, snacks, pasta, bars and plant-based products, as a protein, colour or fortifying ingredient. Strong flavour and odour limit inclusion levels.
• Natural colourant. Phycocyanin extract ("spirulina blue") is widely used as a blue colour in confectionery, beverages, dairy and ice cream because it replaces synthetic blue dyes.
• Malnutrition and public health programmes. Spirulina has been tested as a supplement in undernourished children and people living with HIV in several countries, with mixed and generally low-certainty results.

Additional niches include animal and aquaculture feed, cosmetics (phycocyanin and extracts), and research-grade phycobiliproteins used as fluorescent labels in flow cytometry and immunoassays.

Marketing language often outruns the evidence. Terms such as "detox", "superfood" or "complete protein" are not defined health outcomes. "Complete protein" is technically accurate in terms of essential amino acid content, but spirulina's amino acid score is limited by sulfur-containing amino acids, and practical intakes (a few grams) contribute only a small share of daily protein needs.

Chemical composition

Composition varies with strain, culture conditions, season and drying. The figures below are typical ranges reported in the literature and in commercial specifications, not guaranteed values for any one product.

Component	Typical range (per 100 g dry powder)	Notes
Protein	55–70 g	Complete essential amino acid profile; sulfur amino acids limiting
Carbohydrate	15–25 g	Mainly glycogen-like glucans; low in fibre
Lipid	5–8 g	GLA about 0.5–1.5 g (roughly 15–25% of total fatty acids)
Moisture	3–7 g	Higher moisture raises microbial risk
Ash / minerals	6–13 g	Varies strongly with growth medium
C-phycocyanin	10–20 g	Pigment-protein; less in processed or heat-damaged material
Chlorophyll a	About 0.8–1.5 g	Green pigment
Total carotenoids	About 0.2–0.5 g	β-carotene, zeaxanthin, others
Iron	About 30–100 mg	Often higher in marketing than in absorbed iron
Vitamin B12 (as measured)	Up to about 150–250 µg	Largely pseudovitamin B12

Amino acids. Spirulina supplies all nine essential amino acids. Compared with the FAO/WHO reference pattern, the limiting amino acids are typically methionine plus cysteine and sometimes lysine. Protein digestibility is high, commonly reported around 80–90%, because the cell wall lacks cellulose. Protein efficiency ratios in animal studies are below casein but above many plant proteins.

Fatty acids. The main fatty acids are palmitic (16:0), linoleic (18:2 n-6) and γ-linolenic acid (18:3 n-6). Spirulina contains almost no EPA or DHA, which matters because it is sometimes marketed as an omega-3 source.

Vitamins and minerals. Spirulina provides provitamin A as β-carotene, vitamin K, riboflavin, thiamine and vitamin E, along with potassium, magnesium and iron. At normal supplement doses (1–5 g) the micronutrient contribution is small. Iodine content is variable, and measured B12 values are misleading, as discussed below.

Pseudovitamin B12. Assays based on microbiological growth overstate the B12 in spirulina. Analyses of dried spirulina (Watanabe et al., 1999) found that most of the corrinoid is pseudovitamin B12, an adenine analogue that is not active in humans. Spirulina should therefore not be used as the sole B12 source in vegan or vegetarian diets.

Key active compounds

Spirulina's biological activity is attributed to several constituents, but which one drives a given clinical effect is rarely established. Most mechanistic work uses isolated compounds, not whole-biomass supplements.

C-phycocyanin (C-PC) and phycocyanobilin (PCB). C-PC is a water-soluble light-harvesting pigment-protein made of α and β subunits that covalently bind the open-chain tetrapyrrole phycocyanobilin. In vitro, C-PC and free PCB scavenge radicals, and PCB resembles bilirubin structurally. A widely cited hypothesis (McCarty and colleagues) is that PCB inhibits NADPH oxidase and so lowers oxidative stress. Evidence for this comes mostly from cell and animal experiments; whether meaningful amounts of intact PCB reach tissues after oral dosing in humans is unproven.

Allophycocyanin and phycoerythrin-type pigments. Allophycocyanin is also present and shows antioxidant and anti-inflammatory activity in vitro. It is less studied.

γ-Linolenic acid (GLA). An n-6 polyunsaturated fatty acid that is converted to dihomo-γ-linolenic acid and then to anti-inflammatory eicosanoids. Spirulina is one of the few food sources of GLA besides evening primrose, borage and blackcurrant oils, but the absolute amount in a 3 g dose is small, roughly 15–40 mg.

Carotenoids. β-carotene (provitamin A), zeaxanthin and myxoxanthophyll contribute antioxidant activity and, for β-carotene, vitamin A activity.

Chlorophyll a and its derivatives. Contribute to colour and antioxidant activity in vitro. Absorption in humans is limited.

Sulfated polysaccharides (calcium spirulan). Isolated from A. platensis, these showed antiviral activity against enveloped viruses in cell culture (Hayashi and colleagues). No human antiviral benefit from oral spirulina has been demonstrated.

Phenolic compounds and bioactive peptides. Protein hydrolysates and peptides released by digestion show antioxidant, antihypertensive (ACE-inhibitory) and other activities in vitro and in animals.

Minerals and trace elements. Contribute to nutritional value, with iron and magnesium being the most relevant at supplement doses.

Caveat. The best-defined bioactive in the matrix, C-phycocyanin, is also heat-, light- and acid-labile and digested in the gut, so the compound studied in the lab is not necessarily the compound exposed to the body.

Extraction and processing

Spirulina is sold either as whole dried biomass or as fractions. Processing choices change what the consumer actually receives.

Whole biomass processing. After harvest and washing, the paste is dried. Spray-drying gives a fine powder with short heat exposure; low-temperature belt drying preserves pigments; open sun drying is cheap but raises contamination and degradation risks. Powder may be compressed into tablets, which need binders, or filled into capsules. Some manufacturers use cell disruption (milling, high-pressure homogenisation) to improve release of intracellular contents.

Phycocyanin extraction. C-PC is extracted from fresh or dried biomass by cell disruption (freeze-thaw, sonication, homogenisation or osmotic shock) in water or a mildly acidic phosphate or citrate buffer. The blue extract is clarified by centrifugation or filtration, concentrated, and optionally purified by ammonium sulfate precipitation, chromatography or aqueous two-phase systems. Final products are liquid or spray- or freeze-dried powders, often stabilised with sugars or preservatives.

Other extracts. Lipid extracts (GLA-rich oil, supercritical CO2), polysaccharide fractions and protein isolates are produced at smaller scale. Defatted or decolourised spirulina protein concentrates are used to reduce taste and colour in foods.

Stability constraints.

• C-PC denatures at high temperature (stability falls sharply above roughly 45–50 °C) and is most stable around pH 5.5–6.0.
• Light and oxygen accelerate pigment loss, so powders should be protected from both.
• High-heat cooking or baking reduces phycocyanin content and may change flavour.

Solvent and residue considerations. Water-based extraction is preferred for food products. Organic solvent extraction, used for chlorophyll or carotenoids, requires solvent residue testing against food-grade limits.

Standardization and potency

There is no universal pharmacopoeial standard for spirulina potency, and clinical trials rarely report standardised markers. Whole-biomass products are generally specified by composition, not by a single "active".

Parameter	Typical specification	Method
Protein	≥ 55–60%	Kjeldahl or Dumas nitrogen × 6.25 (overestimates true protein slightly)
C-phycocyanin	≥ 10–15% (premium products higher)	Spectrophotometry (A620, A652)
Moisture	≤ 7%	Loss on drying
Total plate count	Per buyer or regional limits	Culture methods
Lead, arsenic, cadmium, mercury	Per regional limits	ICP-MS
Microcystins	Commonly ≤ 1 µg/g	ELISA, LC-MS/MS

Phycocyanin purity. Purity of extracts is expressed as the ratio of absorbance at 620 nm (phycocyanin) to 280 nm (total protein). Ratios of about 0.7 are typical for food-grade material, about 2.0 for reagent grade, and 4.0 or more for analytical grade. Colourant potency is often stated in colour value units (for example E1%) instead of mass percentage.

What is not standardised. GLA, carotenoid and chlorophyll contents are seldom guaranteed on labels. Because different strains, drying methods and storage times give different pigment levels, two products with the same gram dose can deliver quite different amounts of phycocyanin.

Practical implication for interpreting trials. Most positive trials used a defined commercial product, and results may not transfer to other products. Where a study reports the product's origin and phycocyanin content, that information is more useful than the dose alone.

Mechanisms of action

Proposed mechanisms are largely derived from cell and animal studies. They are plausible and consistent with observed effects, but few have been confirmed in humans.

1. Antioxidant activity. C-PC and PCB scavenge reactive oxygen species in vitro, and spirulina increases activity of endogenous antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase) in animal models. Proposed pathways include NADPH-oxidase inhibition and activation of the Nrf2 / heme oxygenase-1 axis. In human trials, effects on plasma antioxidant capacity and lipid-peroxidation markers (such as malondialdehyde) are reported but inconsistent.

2. Anti-inflammatory signalling. Spirulina extracts reduce NF-κB activation, COX-2 expression and pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) in cell and animal models. In allergic rhinitis models and small human trials, reductions in IL-4 have been reported.

3. Immune modulation. Spirulina and its polysaccharide fractions activate macrophages, natural killer cells and dendritic cells in animal and in vitro studies, and may enhance antibody responses. This immune stimulation is the plausible basis for both potential benefit and the rare reports of autoimmune flares.

4. Lipid metabolism. Proposed mechanisms include reduced hepatic cholesterol and triglyceride synthesis, increased lipoprotein lipase activity, increased faecal bile acid excretion and lower intestinal cholesterol absorption (partly attributed to protein and polysaccharide fractions). Pigment-mediated effects on AMPK and PPAR signalling are also reported in animals.

5. Glucose metabolism and insulin sensitivity. Animal and cell data suggest improved insulin signalling, reduced hepatic gluconeogenesis and reduced oxidative stress in pancreatic β-cells.

6. Blood pressure. Proposed routes are increased endothelial nitric oxide production, reduced vascular oxidative stress and ACE-inhibitory peptides released on digestion.

7. Antiviral and antimicrobial effects. Shown in vitro, notably for calcium spirulan against enveloped viruses. These results have not been replicated as clinical benefit.

8. Nutritional effects. In deficiency settings, spirulina provides protein, iron and provitamin A, which can improve nutritional status independent of any pharmacological mechanism.

Interpretation. Because the same compound is often credited with antioxidant, anti-inflammatory and metabolic effects, mechanistic claims should be treated as hypotheses. Direct human evidence that intact phycocyanin or PCB reaches target tissues at relevant concentrations is lacking.

Pharmacokinetics

Formal human pharmacokinetic data for spirulina constituents are scarce. Spirulina is a complex food matrix, and the usual absorption, distribution, metabolism and excretion (ADME) framework applies component by component.

Absorption and digestion. Spirulina proteins, including C-phycocyanin, are expected to be hydrolysed by gastric and pancreatic proteases into amino acids and short peptides, which are absorbed through standard transporters. Gastric acid and heat-labile structure make intact C-PC absorption unlikely, although small peptides containing the PCB chromophore may form during digestion. Direct measurement of PCB or C-PC in human plasma after oral spirulina has not been established in well-validated studies.

Distribution. Animal studies using labelled or purified phycocyanin report tissue distribution after intravenous or intraperitoneal dosing; those routes do not reflect oral use. For lipophilic constituents, carotenoids are absorbed with dietary fat and carried in lipoproteins, as for other carotenoid sources.

Metabolism. Amino acids enter normal metabolic pools. GLA is elongated and desaturated to dihomo-γ-linolenic acid. Carotenoids undergo conversion (β-carotene to retinol) and standard hepatic handling. PCB, if absorbed, is chemically related to bilirubin and may be metabolised by similar routes, but this is not demonstrated.

Excretion. Unabsorbed fibre-like and polysaccharide material and a proportion of pigments leave in faeces, which can turn stools green. Metabolites of absorbed nutrients follow standard routes.

Key data gap. No robust human dose-concentration curves exist for phycocyanin, PCB or any "signature" spirulina bioactive, which weakens the link between mechanism studies and clinical outcomes.

Bioavailability

Bioavailability differs by component, so a single statement about "spirulina bioavailability" is misleading.

Component	Bioavailability picture	Confidence
Protein / amino acids	High; digestibility commonly reported around 80–90%	Moderate–high
Iron	Present but absorption from spirulina appears moderate; phytate and other factors matter	Low–moderate
β-carotene	Absorbed with dietary fat; conversion to vitamin A occurs	Moderate
GLA	Absorbed as other dietary fatty acids	Moderate
C-phycocyanin / PCB	Poorly characterised; intact absorption unlikely	Low
Vitamin B12	Pseudovitamin B12 is largely inactive in humans	High that it is unreliable
Polysaccharides	Mostly not absorbed; may act in the gut	Low

Factors that change bioavailability.

• Cell wall integrity. The cell wall is not cellulose-based, which makes spirulina easier to digest than Chlorella. Milling or spray-drying can further increase release of contents.
• Dosage form. Tablets with poor disintegration may reduce release; powders and capsules generally disintegrate readily.
• Food matrix. Taking powder with fat-containing food supports carotenoid absorption; vitamin C may support non-heme iron uptake.
• Heat and storage. Cooking, light and long storage lower phycocyanin levels before ingestion.
• Gut factors. Gastric acidity, transit time and the microbiota affect the fate of pigments and polysaccharides.

No spirulina-specific enhancer (for example a piperine-type absorption booster) has been validated.

Preclinical evidence summary

The preclinical literature on spirulina is large and mostly positive, which is typical for natural-product research and partly reflects publication bias. It should be read as hypothesis-generating.

• Lipids and liver. In high-fat-diet and hypercholesterolaemic rodent models, spirulina lowers total and LDL cholesterol and triglycerides and reduces hepatic steatosis and liver enzymes.
• Glucose and insulin. Rodent diabetes and insulin-resistance models show lower fasting glucose and improved insulin sensitivity, with reduced oxidative stress in pancreatic and hepatic tissue.
• Hypertension. Spontaneously hypertensive rats show reduced blood pressure and improved endothelial function after spirulina or its protein hydrolysates.
• Inflammation and immunity. Reductions in inflammatory cytokines and altered immune-cell activity appear in models of colitis, arthritis and allergy, and in macrophage cell lines.
• Neuroprotection. Models of ischaemic stroke, Parkinsonian toxins and neuroinflammation report protective effects, mostly with C-phycocyanin.
• Toxicant protection. Spirulina reduces damage from heavy metals (lead, cadmium, arsenic), radiation and drug-induced organ toxicity in animals.
• Anticancer effects. Phycocyanin and polysaccharide fractions inhibit tumour cell growth in cell culture and some xenograft models. A small oral-leukoplakia trial in tobacco chewers in India (Mathew and colleagues, 1995) is often cited, but it is old and small.
• Antiviral activity. Calcium spirulan and extracts inhibit enveloped viruses in vitro.

Limitations. Many studies use purified phycocyanin or extracts at doses that, scaled to humans, exceed practical intake. Several use injection routes, vary in product quality, and lack blinding or randomisation. Few include dose-response designs. Effects in cell culture rarely translate directly to oral dosing in humans.

Human clinical evidence summary

Human trials of spirulina are numerous but mostly small (often under 100 participants), short (4–24 weeks), and conducted with different products and doses. Meta-analyses help but inherit these limitations. Below, each outcome summarises the direction and quality of the evidence.

Blood lipids. This is the best-supported outcome. A meta-analysis of randomised trials (Serban et al., 2016) found that spirulina supplementation lowered total cholesterol, LDL-C and triglycerides and raised HDL-C. A prospective Cretan study (Mazokopakis et al., 2014) gave 1 g/day for 12 weeks and reported lower total cholesterol, LDL-C and triglycerides. Effect sizes are modest, and heterogeneity and trial quality limit certainty.

Blood pressure. Several trials and meta-analyses report small reductions in systolic and diastolic pressure, more consistently in people with raised baseline values and at doses of about 2 g/day or more. Results across studies are mixed, and the effect is smaller than that of standard antihypertensive drugs.

Glycaemic control. Small trials in people with type 2 diabetes (for example Parikh et al., 2001, 2 g/day for 2 months) report lower fasting glucose and HbA1c, and meta-analyses suggest modest improvements. Study quality is variable, and spirulina should not replace diabetes treatment.

Exercise performance and oxidative stress. Kalafati et al. (2010) gave 6 g/day for 4 weeks to moderately trained men and reported longer time to fatigue and increased fat oxidation, with a rise in markers of antioxidant status. Other trials show small or inconsistent effects on performance and muscle damage markers.

Allergic rhinitis. Cingi et al. (2008) reported symptom improvement with 2 g/day for 6 months compared with placebo, and Mao et al. (2005) reported reduced IL-4 production. The trials are small and the evidence is low certainty.

Anemia and immune function in older adults. Selmi et al. (2011) reported increased haemoglobin in older adults with anemia of ageing and changes in immune markers after several weeks of about 3 g/day. The study was small, and replication is lacking.

Body weight and metabolic syndrome. Some trials and meta-analyses report small reductions in body weight or waist circumference, usually alongside diet and exercise advice. Effect sizes are small and clinical relevance is uncertain.

Malnutrition and HIV. Programmes in children and adults give variable outcomes, with some improvement in weight and haemoglobin but unclear advantage over standard nutritional support.

Cognition, mood, liver disease, kidney outcomes, cancer. Evidence is preliminary: single small trials, pilot studies or mechanistic data. No firm clinical conclusion can be drawn.

Reviews. Karkos et al. (2011) and later narrative reviews (for example Finamore et al., 2017; Lafarga et al., 2020) conclude that results are encouraging but that larger, well-controlled trials with defined products are needed.

Evidence grading by outcome

Grades are the author's qualitative synthesis. They weigh trial number and size, risk of bias, consistency, directness and clinical relevance. They are not formal GRADE ratings and should be updated as new trials appear.

Outcome	Grade	Rationale
Total and LDL cholesterol, triglycerides	Moderate	Multiple RCTs and a meta-analysis; modest effects; heterogeneity
Blood pressure	Low–moderate	Small reductions; inconsistent across trials
Fasting glucose / HbA1c	Low–moderate	Small trials; modest effect; variable quality
Body weight, waist circumference	Low	Small effects; confounded by diet advice
Exercise endurance / oxidative stress markers	Low	Few trials; inconsistent results
Allergic rhinitis symptoms	Low	Few small trials
Anemia in older adults	Low	One small trial; no replication
Immune function in humans	Low	Surrogate markers; heterogeneous
Nutritional rehabilitation in malnutrition	Low	Mixed results; no clear edge over standard care
Cognition, mood, liver, kidney, cancer outcomes	Very low	Preliminary or mechanistic data only
Antiviral effects in humans	Very low	Cell-culture data only
Vitamin B12 repletion	Not supported	Pseudovitamin B12 is not reliably active in humans

Reading the table. A "low" grade does not mean the effect is absent. It means the data do not allow confidence. In practice, only cardiometabolic outcomes have enough human data to describe a likely, though modest, direction of effect.

Dosages used in studies

Human trials have used a wide range of daily doses. Most fall between 1 and 10 g of dried spirulina per day, with 1–3 g the most common in cardiometabolic and immune studies, and a minority going higher.

Outcome studied	Typical daily dose	Typical duration	Example
Lipids	1–8 g	8–24 weeks	Mazokopakis et al. (1 g, 12 weeks)
Blood pressure	2–4.5 g	6–12 weeks	Various small RCTs
Glycaemic control	2–8 g	8–12 weeks	Parikh et al. (2 g, 2 months)
Exercise and oxidative stress	6 g	4 weeks	Kalafati et al.
Allergic rhinitis	1–2 g	12–24 weeks	Mao et al.; Cingi et al. (2 g, 6 months)
Anemia / immune function in older adults	About 3 g	Several weeks	Selmi et al.
Malnutrition programmes	1–10 g (age-dependent)	Weeks–months	Various field studies

Points to note.

• No dose-response relationship has been firmly established. Some trials show similar effects at 1 g and at higher doses.
• Doses above 10 g/day have been given in short studies, but long-term safety at such levels is not well documented.
• Doses in children are weight- and age-adjusted, and a paediatric regimen should be set by a clinician.
• The doses reflect specific commercial products, and dose equivalence between products is uncertain.

Practical reading. A common supplement intake of 1–5 g/day sits within the range used in trials and has an acceptable safety record when the product is high quality. Higher intakes add cost and potential exposure to contaminants without proven added benefit.

Timing and use

There is no evidence-based optimal time of day for spirulina. Trials have used it once daily or split into two or three doses, mostly with meals.

• With food. Taking spirulina with meals is the usual practice. It lowers the chance of nausea, supports carotenoid absorption with dietary fat, and matches most trial protocols.
• Split doses. Doses of 3 g or more are often divided across the day to improve tolerance.
• Morning versus evening. Some people report mild stimulation and prefer morning use. This is anecdotal.
• Before exercise. Exercise trials gave spirulina daily for several weeks, so the benefit of acute pre-workout timing is not established.
• Starting dose. Starting at 1 g/day and increasing over one to two weeks may reduce digestive discomfort.
• Duration. Cardiometabolic effects in trials appeared after 4–12 weeks. Long-term (over one year) controlled data are limited.
• Mixing. Powder can be stirred into water, juice or smoothies. Heating above about 45–50 °C degrades phycocyanin.
• Iron and calcium timing. No specific timing rule is established, but anyone on levothyroxine or other narrow-window drugs should ask a pharmacist about spacing, since mineral-rich supplements can interfere with some medicines.

Available forms

Form	Features	Considerations
Powder	Flexible dose; can be mixed into drinks and foods	Strong taste and smell; spills; harder to check quality by eye
Tablets	Convenient, tasteless; common in trials	Binders and excipients; variable disintegration; several tablets per gram
Capsules	Easy to swallow; avoids taste	Typically 500 mg or less per capsule
Flakes / strands	Minimally processed	Less uniform; higher microbial risk if poorly dried
Fresh / frozen paste	Minimal drying; high pigment retention	Short shelf life; limited availability; cold chain needed
Phycocyanin extract (liquid or powder)	Concentrated blue pigment; used as colourant and in supplements	Different product from whole spirulina; stability concerns; not the same evidence base
Spirulina oil / GLA extracts	Concentrated lipid fraction	Rare; separate from whole-biomass evidence
Fortified foods	Pasta, bars, beverages, snacks	Low and variable spirulina content; heat may degrade pigments

Choosing a form. For most people the form matters less than the product's purity and verified composition. Organic or certified labels do not by themselves guarantee absence of contaminants, so third-party testing is a more informative signal than marketing terms (see the quality section).

Safety and side effects

Overall profile. A United States Pharmacopeia safety review (Marles et al., 2011) concluded that spirulina itself has a good safety record at typical doses and that most safety concerns arise from contaminants. Clinical trials at 1–10 g/day for weeks to months generally report adverse events at rates similar to placebo.

Common, mild effects.

• Nausea, bloating, diarrhoea or constipation, especially at the start or at higher doses
• Green-tinted stools
• Unpleasant taste or odour, and headache in some users
• Mild allergic-type reactions in sensitive people

Less common or rare serious events (mostly case reports).

• Autoimmune activation. Lee and Werth (2004) described flares of pemphigus and dermatomyositis in patients taking spirulina or related immunostimulatory supplements. Causality cannot be proven, but the immune-stimulating properties make caution reasonable.
• Rhabdomyolysis. A reported case (Mazokopakis et al., 2008) described acute muscle breakdown in a patient after starting spirulina. Product contamination or co-factors were not fully excluded.
• Allergic reactions, including anaphylaxis. Rare reports exist, particularly in people with other algae or cyanobacteria sensitivity.
• Hepatic effects. Rare reports of liver injury, often with unverified product quality or multi-ingredient products.
• Iron overload. A theoretical concern in people with haemochromatosis or on large intakes, because of spirulina's iron content.

Phenylketonuria. Spirulina protein supplies phenylalanine. People with PKU should avoid it unless their metabolic team has approved its inclusion in their diet.

Contaminant-related toxicity. Microcystins from co-occurring toxic cyanobacteria cause hepatotoxicity, and heavy metals cause cumulative harm. These are discussed in the contamination section.

Long-term safety. Controlled data beyond several months are limited. Populations in Chad and Mexico have eaten spirulina for generations, but at different quantities and with different source conditions than modern supplements.

When to stop. Anyone who develops rash, breathing difficulty, severe abdominal pain, jaundice, dark urine or unexplained muscle pain or weakness should stop spirulina and seek medical care.

Drug and supplement interactions

Formal interaction studies are very limited. The interactions below are theoretical or based on case reports and on known properties of the constituents.

Drug / supplement class	Concern	Strength of evidence
Immunosuppressants (tacrolimus, cyclosporine, corticosteroids, methotrexate, biologics)	Immune-stimulating effects could oppose treatment	Theoretical
Anticoagulants and antiplatelets (warfarin, others)	Vitamin K content (warfarin); possible effects on platelet function	Theoretical; vitamin K amount at normal doses is small but variable
Antidiabetic drugs and insulin	Additive glucose lowering; hypoglycaemia risk	Plausible from trial effects
Antihypertensives	Additive blood-pressure lowering	Plausible from trial effects
Lipid-lowering drugs (statins and others)	Additive lipid effects; rhabdomyolysis case report raises caution	Theoretical
Levothyroxine and other drugs sensitive to mineral binding	Possible reduced absorption with mineral-rich supplements; iodine content varies	Theoretical
Iron supplements	Additive iron intake	Theoretical
Other immune-stimulating supplements (echinacea and similar)	Additive immune activation	Theoretical
Hepatotoxic drugs and supplements	Contaminant risk in poor-quality products	Theoretical

Foods and nutrients. Spirulina is high in vitamin K and iodine relative to its mass, so large intakes may matter for people who need constant dietary intake of these nutrients.

Practical guidance. People taking prescription medicines, especially immunosuppressants, anticoagulants or glucose- and blood-pressure-lowering drugs, should discuss spirulina with a pharmacist or physician before starting, and report it as part of their medication list.

Special populations

Population	Guidance	Basis
Pregnancy and breastfeeding	Insufficient safety data; most professional bodies advise avoiding supplemental use unless a clinician agrees	Absence of trials; contaminant and iodine concerns
Infants and children	Used in nutrition programmes under supervision; supplement use should be guided by a paediatrician	Limited paediatric safety data; dose must be weight-adjusted
Older adults	Studied in small trials; watch for drug interactions and hydration	Selmi et al. and others
Phenylketonuria	Avoid unless approved by the metabolic team	Phenylalanine content
Autoimmune disease (lupus, pemphigus, rheumatoid arthritis, multiple sclerosis, dermatomyositis)	Avoid or use only with specialist advice	Immune stimulation; case reports of flares
Organ transplant recipients and others on immunosuppression	Avoid unless the transplant team approves	Theoretical opposition to immunosuppression
Haemochromatosis or iron overload	Caution	Iron content
Thyroid disease	Caution, since iodine varies by batch	Variable iodine content
Liver disease	Use only high-quality, tested products and with medical advice	Contaminant risk; rare liver reports
Kidney disease	Seek advice; potassium, phosphorus and protein loads can matter	High mineral and protein density
Gout / hyperuricaemia	Caution advised in some sources, since nucleic acid content is relatively high	Purine content; limited clinical data
Allergy to seaweed, algae or cyanobacteria	Avoid or use cautiously	Rare allergic reactions
Before surgery	Stop in advance if advised by the surgical team	Possible effects on blood pressure, glucose and clotting parameters
Athletes	Studied for performance; use certified products, particularly in tested sports	Contamination and anti-doping rules for supplements

Vegetarians and vegans. Spirulina can contribute protein and some iron but is not a reliable source of vitamin B12 or of EPA/DHA, so these nutrients still need dedicated sources.

Quality, testing and authentication

Because safety and potency depend on the batch, quality control is central to spirulina. A trustworthy product has a documented chain from pond to package and supporting analytical data.

Identity testing.

• Microscopy. Confirms the characteristic helical trichomes and detects other algae or cyanobacteria.
• DNA methods. 16S rRNA or marker-gene PCR and sequencing confirm Arthrospira identity and detect co-occurring cyanobacteria, including potential toxin producers.
• Pigment fingerprints. HPLC or spectral profiles of phycocyanin, chlorophyll and carotenoids confirm typical composition.

Potency and composition testing. Protein by nitrogen analysis, phycocyanin by spectrophotometry or HPLC, moisture, ash, and fatty-acid profile (GC-FID) by lab standards.

Safety testing.

• Microcystins and other cyanotoxins. ELISA for screening and LC-MS/MS for confirmation. The commonly cited limit for supplements is 1 µg/g microcystin-LR equivalents (the Oregon health limit, referenced by the USP review).
• Heavy metals. Lead, arsenic, cadmium and mercury by ICP-MS against regional limits.
• Microbiology. Total aerobic count, yeasts and moulds, E. coli, Salmonella, coliforms and Staphylococcus aureus.
• Residues. Pesticides, solvents (for extracts), and, where relevant, radiological screening.

Certification and signals to look for.

• Current Good Manufacturing Practice (cGMP) or equivalent food-safety certification (for example ISO 22000, FSSC 22000)
• Third-party certificates of analysis (COA) for each lot, from an accredited laboratory
• Stated species and country of origin, and stated pond or farm source
• Third-party seals such as USP verification, NSF or similar programmes, where available
• Packaging that limits light and moisture, with a clear expiry date

Limits of organic labelling. Organic certification addresses farming inputs but does not by itself guarantee absence of toxins or heavy metals.

Adulteration and contamination risks

Microcystins and other cyanotoxins. Microcystins are hepatotoxic peptides made by some cyanobacteria, notably Microcystis, and they can contaminate cultures or wild harvests. Arthrospira itself is not known to produce microcystins, so contamination comes from other species that grow alongside it. Gilroy et al. (2000) found microcystins in many blue-green algae supplements, mainly Aphanizomenon-based products from natural lake harvests. Controlled cultivation lowers this risk but does not remove it.

BMAA and other neurotoxins. The non-protein amino acid β-N-methylamino-L-alanine (BMAA) has been detected in some cyanobacterial products, and its health relevance is debated. Analytical results vary with method, and no consensus exists on risk from spirulina supplements.

Heavy metals. Spirulina can accumulate metals from water and nutrient inputs, and poorly controlled sources have shown elevated lead, arsenic, cadmium or mercury. Metal content depends on the growth medium and fertiliser quality, so testing each lot matters.

Microbial contamination. Open ponds, sun drying and weak hygiene can raise bacterial counts or introduce pathogens.

Pesticide and chemical residues. Possible through water or nutrient inputs and, for extracts, through processing solvents.

Economic adulteration. Potential forms include:

• Substitution or dilution with cheaper algae or cyanobacteria (for example, Chlorella or non-spirulina species)
• Bulking with starch, fillers or plant powders
• Colour enhancement with added phycocyanin, chlorophyll or other pigments to mask low quality
• Overstated protein or phycocyanin content on labels

Analytical tools such as microscopy, DNA testing, pigment profiling and nitrogen-to-protein cross-checks can detect many of these problems.

Wild-harvested versus cultivated. Wild blue-green algae carry higher risk of toxin-producing co-species, so cultivated Arthrospira from a controlled source is preferable.

Consumer tips. Prefer brands that publish lot-specific COAs, name the species and origin, test for microcystins and heavy metals, and avoid products with exaggerated claims or no testing information.

Regulatory overview

Regulation of spirulina differs by region and by use (food, supplement or colour). The summary below is general, was written from the author's knowledge, and should be checked against current official sources before any commercial or legal use.

Region	Typical status	Notes
United States	Dietary supplement ingredient and food ingredient (DSHEA framework); GRAS notices exist for some uses	No health claims are pre-approved; structure/function claims must be substantiated and carry the FDA disclaimer
United States (colour)	Spirulina extract is a listed colour additive exempt from certification (21 CFR 73.530)	Approved from 2013 for limited foods, with later expansions to more food categories
European Union	Traditional food, not a novel food, because of history of use before 1997	Spirulina extract is often handled as a "colouring foodstuff"; no authorised EU health claims specific to spirulina
India	Regulated as food or nutraceutical under FSSAI health supplement and nutraceutical rules	Check the current FSSAI schedule for permitted forms, limits and labelling
Canada	Natural health product (NHP) pathway; some products licensed	Contaminant limits and licensing conditions apply
Other markets	Mostly food or supplement	Contaminant limits, labelling and claims vary

Contaminant limits. Some authorities and jurisdictions set specific limits (for example 1 µg/g microcystin in Oregon), while others rely on general food safety law and metal limits for foods and supplements.

Claims. Disease-treatment claims are drug claims in most jurisdictions. Supplement labels may be limited to nutrient content or general wellness statements.

Sports and anti-doping. Spirulina is not prohibited, but any supplement can be contaminated, and athletes in tested sports should use independently certified products.

Status can change. Regulatory positions, colour approvals and novel-food decisions are revised over time, so verify current rules in the relevant market.

Research gaps

1. Product standardisation in trials. Most trials do not report strain, phycocyanin content, contaminant levels or drying method, which makes results hard to compare or replicate.
2. Human pharmacokinetics. There are no validated measurements of phycocyanin, PCB or other pigments in human plasma or tissues after oral spirulina, and no dose-exposure data.
3. Larger, longer RCTs. Typical trials enrol under 100 people for under 6 months. Large, pre-registered, double-blind trials of 6–12 months or more are needed, with clinical endpoints and not just biomarkers.
4. Dose-response and optimal dose. No clear relationship between dose and effect has been established.
5. Active-constituent attribution. Whole biomass versus phycocyanin-enriched or phycocyanin-depleted fractions have not been compared in humans.
6. Long-term safety. Chronic use over years, including effects on immunity, kidney and liver, needs systematic follow-up and post-marketing surveillance.
7. Immune effects in autoimmune and transplant populations. Case reports raise a signal that has not been tested in controlled studies.
8. Special populations. Few data exist for pregnancy, breastfeeding, children and people with chronic disease.
9. Contaminant surveillance. Systematic, current data on microcystins, BMAA and metals across commercial products and regions are limited.
10. Publication bias and risk of bias. Positive small trials and a high proportion of industry-funded or regionally clustered studies call for independent replication.
11. Environmental and nutritional claims. Comparative life-cycle assessments and real-world protein-contribution studies at realistic intakes are limited.
12. Gut microbiome interactions. Early data on spirulina and the gut microbiota need confirmation in controlled human work.

Frequently asked questions

Is spirulina an algae? No. It is a cyanobacterium, a bacterium that photosynthesises. The term "blue-green algae" is a historical label.

Is spirulina a complete protein? It contains all nine essential amino acids, but sulfur-containing amino acids are limiting, and typical supplement doses (1–5 g) add only a few grams of protein.

Can spirulina replace vitamin B12? No. Most of its B12-like content is pseudovitamin B12, which is not reliably active in humans.

How much spirulina is safe per day? Trials mainly use 1–10 g/day, and most healthy adults tolerate this range when the product is clean. Long-term data are limited, and no official upper limit exists in most regions.

Does spirulina lower cholesterol? Meta-analytic evidence suggests modest reductions in LDL-C and triglycerides. It is not a substitute for prescribed lipid-lowering treatment.

Does spirulina help weight loss? Effects on weight are small and uncertain. It does not replace diet and activity changes.

Does spirulina detoxify heavy metals? Animal studies suggest protective effects, but human evidence is minimal. "Detox" claims are not supported. Poor-quality spirulina can itself contain heavy metals.

Is spirulina safe in pregnancy? Data are insufficient, so supplemental use should be discussed with a clinician.

Can I take spirulina with medications? Some combinations need caution, especially immunosuppressants, anticoagulants, and glucose- or blood-pressure-lowering drugs. Check with a pharmacist or physician.

Why does spirulina turn stools green? Pigments, mainly chlorophyll, pass through the gut. This is harmless.

What does spirulina taste like? Earthy, sea-like and slightly bitter. Blending with fruit, mixing into smoothies or using capsules reduces the taste.

How can I tell if a product is good? Look for a named species, country of origin, current lot-specific COA with microcystin, heavy-metal and microbial results, appropriate certifications and sensible claims.

Is phycocyanin the same as spirulina? No. Phycocyanin is one pigment-protein extracted from spirulina. Evidence for whole spirulina should not be assumed to apply to extracts, and vice versa.

Does cooking destroy spirulina's nutrients? Heat above about 45–50 °C degrades phycocyanin, but protein and minerals remain largely intact.

Scientific references

These references were compiled from the author's knowledge of the literature without live database lookup. Volume, page and year details should be verified (for example in PubMed) before publication.

1. Cingi C, Conk-Dalay M, Cakli H, Bal C. The effects of spirulina on allergic rhinitis. Eur Arch Otorhinolaryngol. 2008;265(10):1219–1223.
2. Finamore A, Palmery M, Bensehaila S, Peluso I. Antioxidant, immunomodulating, and microbial-modulating activities of the sustainable and ecofriendly spirulina. Oxid Med Cell Longev. 2017;2017:3247528.
3. Gilroy DJ, Kauffman KW, Hall RA, Huang X, Chu FS. Assessing potential health risks from microcystin toxins in blue-green algae dietary supplements. Environ Health Perspect. 2000;108(5):435–439.
4. Kalafati M, Jamurtas AZ, Nikolaidis MG, et al. Ergogenic and antioxidant effects of spirulina supplementation in humans. Med Sci Sports Exerc. 2010;42(1):142–151.
5. Karkos PD, Leong SC, Karkos CD, Sivaji N, Assimakopoulos DA. Spirulina in clinical practice: evidence-based human applications. Evid Based Complement Alternat Med. 2011;2011:531053.
6. Lafarga T, Fernández-Sevilla JM, González-López C, et al. Spirulina for the food and functional food industries. Food Res Int. 2020;137:109356.
7. Lee AN, Werth VP. Activation of autoimmunity following use of immunostimulatory herbal supplements. Arch Dermatol. 2004;140(6):723–727.
8. Mao TK, Van de Water J, Gershwin ME. Effects of a Spirulina-based dietary supplement on cytokine production from allergic rhinitis patients. J Med Food. 2005;8(1):27–30.
9. Marles RJ, Barrett ML, Barnes J, et al. United States Pharmacopeia safety evaluation of spirulina. Crit Rev Food Sci Nutr. 2011;51(7):593–604.
10. Mazokopakis EE, Karefilakis CM, Tsartsalis AN, Milkas AN, Ganotakis ES. Acute rhabdomyolysis caused by Spirulina (Arthrospira platensis). Phytomedicine. 2008;15(6–7):525–527.
11. Mazokopakis EE, Starakis IK, Papadomanolaki MG, Mavroeidi NG, Ganotakis ES. The hypolipidaemic effects of Spirulina (Arthrospira platensis) supplementation in a Cretan population: a prospective study. J Sci Food Agric. 2014;94(3):432–437.
12. Parikh P, Mani U, Iyer U. Role of Spirulina in the control of glycemia and lipidemia in type 2 diabetes mellitus. J Med Food. 2001;4(4):193–199.
13. Selmi C, Leung PSC, Fischer L, et al. The effects of Spirulina on anemia and immune function in senior citizens. Cell Mol Immunol. 2011;8(3):248–254.
14. Serban MC, Sahebkar A, Dragan S, et al. A systematic review and meta-analysis of the impact of Spirulina supplementation on plasma lipid concentrations. Clin Nutr. 2016;35(4):842–851.
15. Watanabe F, Katsura H, Takenaka S, et al. Pseudovitamin B12 is the predominant cobamide of an algal health food, spirulina tablets. J Agric Food Chem. 1999;47(11):4736–4741.
16. Zarrouk C. Contribution à l'étude d'une cyanophycée. Influence de divers facteurs physiques et chimiques sur la croissance et la photosynthèse de Spirulina maxima. PhD thesis, University of Paris; 1966.